Efficacy of infliximab in long-lasting refractory Kawasaki disease [2]

Clinical and Experimental Rheumatology

Volumn 24, Issue 4, 2006, Pages 453-

  Zulian, Francisco ^b   Zanon, G ^b   Martini, G ^b   Mescoli, G ^a   Milanesi, O ^b  

^a MAGGIORE HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; HEMOGLOBIN; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; PREDNISONE; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; WARFARIN;

ANGIOCARDIOGRAPHY; CASE REPORT; CERVICAL LYMPHADENOPATHY; CONJUNCTIVITIS; CORONARY ARTERY ANEURYSM; CORONARY ARTERY CIRCUMFLEX BRANCH; DRUG EFFICACY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEVER; FOLLOW UP; HEART MUSCLE ISCHEMIA; HEART SCINTISCANNING; HOSPITAL ADMISSION; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LETTER; LEUKOCYTE COUNT; MALAISE; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUCOSA INFLAMMATION; PERICARDIAL EFFUSION; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RIGHT CORONARY ARTERY; SACCULAR ANEURYSM; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ASPIRIN; CHILD, PRESCHOOL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WARFARIN;

EID: 33748574875     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (11)

1. HAN RK, SILVERMAN ED, NEWMAN A, MC CRINDELE BW: Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med 2000; 154: 694-9.
2. FALCINI F, CIMAZ R, CALABRI GB et al.:Kawasaki disease in northern Italy: a multicenter retrospective study of 250 patients. Clin Exp Rheumatol 2002; 20: 421-6
3. BURNS JC, CAPPARELLI EV, BROWN JA, NEWBURGER JW, GLOBE MP: Intravenous gamma-globulin treatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998; 17: 1144-8.
4. WALLACE CA, FRENCH JW, KAHN SJ, SHERRY DD: Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105: E78.
5. HASHINO K, ISHII M, IEMURA M, AKAGI T, KATO H: Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 200 1; 43: 211-7.
6. DURONGPISITKUL K, SOONGSWANG J, LAOHAPRASITIPORN D, NANA A, PRANCHUABMOBH C, KANGKAGATE C: Immunoglobulin failure and re-treatment in Kawasaki disease. Pediatr Cardiol 2003;24:145-8.
7. WRIGHT DA, NEWBURGER JW, BAKER A, SUNDEL RP: Treatment of immunoglobulin resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;123:146-9.
8. FREEMAN AF, SHULMAN ST: Refractory Kawasaki disease. Pediatr Infect Dis J 2004; 23: 463-4.
9. MATSUBARA T, FURUKAWA S, YABUTA K: Serum levels of tumor necrosis factor, interleukin-2 receptor and interferon-y γ in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990; 56: 29-36.
10. WEISS JE, EBERHARD BE, CHOWDHURY D, GOTTLIEB BS: Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004; 31: 808-10.
11. BURNS JC, MASON WH, HAUGER BS et al.: Infliximab treatment for refractory Kawasaki Syndrome. J Pediatr 2005 146: 662-7.